A phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer

A phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer - A phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001234

Enrollment

Registered

2008-07-08

Start date

2006-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

Carboplatin+Paclitaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NSCLC,Stage III V20 and less 35% Performance status 0-1 Measurable lesion Adequate organ function Written informed consent

Exclusion criteria

Exclusion criteria: Pulmonary fibrosis Previous treatment of thoracic irradiation Active co-existing malignancy

Design outcomes

Primary

Measure	Time frame
recommended dose of radiotherapy	—

Secondary

Measure	Time frame
Toxicity, response, overall survival	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026